| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
25(S)-Ruscogenin-1-O-α-L-rhamnopyranosyl (1→2)-β-D-xylopyranoside shows inhibitory activity of neutrophil respiratory burst stimulated by PMA (phorbol myristate acetate). It targets neutrophils and inhibits their activation. Its mechanism may involve modulation of NADPH oxidase or other signaling pathways involved in respiratory burst.
|
|---|---|
| ln Vitro |
In vitro, 25(S)-Ruscogenin-1-O-α-L-rhamnopyranosyl (1→2)-β-D-xylopyranoside inhibits neutrophil respiratory burst stimulated by PMA. This indicates anti-inflammatory activity through inhibition of neutrophil activation. It may also have other biological activities as a steroidal saponin.
|
| ln Vivo |
In vivo studies for 25(S)-Ruscogenin-1-O-α-L-rhamnopyranosyl (1→2)-β-D-xylopyranoside are limited. Its inhibition of neutrophil respiratory burst suggests potential anti-inflammatory effects in vivo. Animal models of inflammation would be needed to confirm its efficacy and safety.
|
| Enzyme Assay |
Cell-free assays for 25(S)-Ruscogenin-1-O-α-L-rhamnopyranosyl (1→2)-β-D-xylopyranoside: neutrophil respiratory burst is measured using chemiluminescence or cytochrome c reduction assays. Neutrophils are isolated from blood and stimulated with PMA in the presence or absence of the compound. Superoxide production is measured and IC50 values are calculated.
|
| Cell Assay |
Cellular assays for 25(S)-Ruscogenin-1-O-α-L-rhamnopyranosyl (1→2)-β-D-xylopyranoside: neutrophils are isolated from human or animal blood and treated with the compound at concentrations of 0.1-100 µM for 30-60 minutes, then stimulated with PMA. Respiratory burst is measured by chemiluminescence or nitroblue tetrazolium reduction. Cell viability is assessed to rule out cytotoxicity.
|
| Animal Protocol |
In vivo animal studies for 25(S)-Ruscogenin-1-O-α-L-rhamnopyranosyl (1→2)-β-D-xylopyranoside: animal models of inflammation (e.g., carrageenan-induced paw edema or LPS-induced lung inflammation) would be used. Animals are administered the compound orally or intraperitoneally at doses of 10-50 mg/kg. Neutrophil infiltration and activation are assessed in tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 25(S)-Ruscogenin-1-O-α-L-rhamnopyranosyl (1→2)-β-D-xylopyranoside: as a steroidal saponin with molecular weight 708.88, it may have poor oral bioavailability. It is likely metabolized by intestinal flora and liver enzymes. Tissue distribution and elimination pathways require further investigation.
|
| Toxicity/Toxicokinetics |
Toxicity of 25(S)-Ruscogenin-1-O-α-L-rhamnopyranosyl (1→2)-β-D-xylopyranoside: comprehensive toxicity data are limited. As a saponin, it may have hemolytic activity and gastrointestinal effects at high doses. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
It has been reported that onions contain 25(S)-Ruscogenin 1-OI<<-L-rhamnopyranosyl-(1 L2)-EC-D-xylopyranoside, and there is relevant data.
25(S)-Ruscogenin-1-O-α-L-rhamnopyranosyl (1→2)-β-D-xylopyranoside is a research compound with potential applications in anti-inflammatory research. It is available as a reference standard for pharmacological studies. Its mechanism involves inhibition of neutrophil respiratory burst. No clinical trials or FDA approvals have been reported. |
| Molecular Formula |
C38H60O12
|
|---|---|
| Exact Mass |
708.408
|
| CAS # |
125225-63-0
|
| PubChem CID |
3509806
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
50
|
| Complexity |
1300
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(C(CC(C6)O)OC7C(C(C(CO7)O)O)OC8C(C(C(C(O8)C)O)O)O)C)C)C)OC1
|
| InChi Key |
SKHJNNFXCKTDBG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C38H60O12/c1-17-8-11-38(46-15-17)18(2)28-26(50-38)14-24-22-7-6-20-12-21(39)13-27(37(20,5)23(22)9-10-36(24,28)4)48-35-33(30(42)25(40)16-45-35)49-34-32(44)31(43)29(41)19(3)47-34/h6,17-19,21-35,39-44H,7-16H2,1-5H3
|
| Chemical Name |
2-[4,5-dihydroxy-2-(16-hydroxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-14-yl)oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
